1Department of Pharmacognosy, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute (Deemed to be Univ), Velappanchavadi, Chennai - 600077
2Department of Pharmaceutical Chemistry and Analysis, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute (Deemed to be Univ), Velappanchavadi, Chennai - 600077
3Pharma Buddy, Faculty of Pharmacy, Dr. M.G.R Educational and Research Institute (Deemed to be Univ), Velappanchavadi, Chennai - 600 077
4Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar, Chidambaram
*Corresponding Author E-mail: dhanadinesh2011@gmail.com
Online published on 25 August, 2021.
Endometrial carcinoma (EC) is the most common gynecologic malignancy in the United States. Prognosis depends on patient age, histological grade, depth of myometrial invasion and/or cervical invasion, and the presence of lymph node metastases. Although EC is staged surgically according to the International Federation of Gynecology and Obstetrics (FIGO) system, preoperative imaging can assist in optimal treatment planning. Several imaging techniques such as transvaginal ultrasonography (TVUS), computed tomography (CT), and magnetic resonance imaging (MRI) have been used as diagnostic tools for preoperative staging of EC. Recently, positron emission tomography (PET), PET/CT, and PET/MRI have also been used in staging these patients. In this article, we review stageing, risk factors, value of imaging in diagnosis, recent research on treatment planning, and detection of recurrent disease in patients with EC.
Endometrial cancer, Prognosis, Diagnosis, Treatment (chemotherapy)
